


# Implementing a web-based Research Information System as a Tool for Knowledge management and Performance Monitoring at the Institut Pasteur de Tunis

Najet Hadhri  
Dubrovnik, May 13, 2022



# Institut Pasteur de Tunis Tunis



1893

Founded

1903

Charles Nicolle  
Director General



1928


Nobel Medicine  
Prize



1936

**Major discoveries on:**  
Typhus  
Toxoplasma  
Leishmaniasis  
Inapparent disease

# Missions and authorities



# Programmes Collaboratifs Internes



World Health  
Organization




PTR & ACIP  
Institut Pasteur



PHiND  
access





# PHINDaccess 2018-2022

**Pathogen-Host Interaction Data access**

**Strengthening Omics Data Analysis Capacities in Pathogen-Host Interaction**



## Support Services for R&I Promotion and Valorization

Unleashing IPT's full potential for an efficient translational research

Setup of Knowledge Management integrated Platform




Fostering Fundraising and Grants Management Capacities Workflow

Performance monitoring and strategy for sustainable networking and excellence

Grants Office

Technologies Transfer Office

# Research lifecycle and Ecosystem



# Common questions for Performance Monitoring / Challenges

How access to appropriate and up-to-date data sets?

Allocated resources?

Budget, fundraising and budget uptake

What we have produced? during specific periods?

Institution, Department, Researcher

With who researchers we are doing research?

Partners, National, international

What are relevant funding instrument ?

Obtained or to target

Research specialist and expert?

- Time consuming for data collection and double check, unavailability of some output data (Projects)

- A lot of sources of unstructured information, Limited to publications only

- Research activities and outputs are not findable at Institute/National level (Projects and Publications), Coverage discrepancy, Restricted access

- Research community is not enough aware about research happening within organization

# RIM System: Advantages R&D ecosystem stakeholders

## Scientists

- ✓ Ensure research outputs are available and findable and re-usable
- ✓ Reduce the repetitive data entry
- ✓ Enhance the outputs' visibility for networking, collaboration and knowledge dissemination
- ✓ Increasing fundraising performance and access to funding opportunities

## Management


- ✓ Reduce the time to collect research related information for reporting and decision making
- ✓ Facilitate to administrator to build performance assessment report
- ✓ Easiest access up-to-date and customized metrics
- ✓ Enable the set up of efficient Scouting system, Sourcing

## Funding Agencies and Policy Makers

- ✓ Assisting Policy Makers and Funding Agencies by providing research related information, which includes
- ✓ Support to the funding agencies and policy makers to identify experts for project proposal review and various committees

# Web-based Research Information Management: Goals

- Insight tool aiming to provide easy access to research information pertaining to publications, awarded projects, and relevant funding programs.



- Sustaining access to an operational workflow exhaustive outputs record and customized metrics.

# Web-based Research Information Management

## Funding

Database of relevant funding programs and calls for proposals



## Grants Workflow

Help to assess applications and manage pre-award phase



## Institutional Repositories

Increase the visibility and facilitate access to information related Publications and awarded Projects



## Metrics

Consolidated dashboard with a customized KPIs



# KPIs → R&I strategy

## Publication track record



|                                                  | IPT   | IP    | CRG   |
|--------------------------------------------------|-------|-------|-------|
| Number of permanent staff researchers/2016       | 123   | 1131  | 95    |
| Publications*                                    | 572   | 5763  | 1183  |
| H-index*                                         | 24    | 99    | 73    |
| Publications/researcher                          | 4,65  | 5,10  | 12,45 |
| Publications Top %10*                            | 7,69  | 19,54 | 26,46 |
| % Cited documents*                               | 64,16 | 79,77 | 84,28 |
| Citation Impact*                                 | 4,52  | 14,87 | 27,92 |
| %Publications with International Collaborations* | 56,47 | 57,9  | 64,33 |
| % Publications with industrial partners*         | 0,22  | 2,72  | 4,06  |

## Knowledge & Technology transfer (KTT)

|                          |      |      |      |
|--------------------------|------|------|------|
| Patents                  | 15   | 1451 | 34   |
| Patents/researcher       | 0,12 | 1,28 | 0,36 |
| KTT agreements*          | 30   | 63   | 41   |
| KT agreement/researcher* | 0,24 | 0,06 | 0,41 |

## EU Framework programs (FP)

|                      |      |      |      |
|----------------------|------|------|------|
| FP7-H2020 projects   | 13   | 142  | 124  |
| FP7-H2020/researcher | 0,11 | 0,13 | 1,31 |





Deadline

Topic

Agency

Search

Clear

# Access Funding

91 Funding

| N                                                | Title                                                                          | Description                                                                                                                                                                                                                                                                                                                                                                                                                                             | Deadline   |
|--------------------------------------------------|--------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| 1                                                | Research Project Grant (Parent R01 Clinical Trial Required) - PA-20-183        | The NIH Research Project Grant supports a discrete, specified, circumscribed project in scientific areas that represent the investigators' specific interests and competencies and that fall within the mission of the participating NIH Institutes and Centers (ICs). All applications submitted to this Parent Funding Opportunity Announcement must <b>propose clinical trial(s)</b> .                                                               | 08-05-2023 |
| <a href="#">Link to Additional Information %</a> |                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |
| 2                                                | NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) - PA-20-185 | The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers based on their scientific missions.<br><br>This Funding Opportunity Announcement does not accept applications proposing clinical trial(s). | 08-05-2023 |
| <a href="#">Link to Additional Information %</a> |                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |



### Funding

By page

|   |                                                                                                          |                                                  |
|---|----------------------------------------------------------------------------------------------------------|--------------------------------------------------|
| 3 | Research Project Grant (Parent R01 Clinical Trial Required) - PA-20-183                                  | <a href="#">Link to Additional Information %</a> |
| 4 | NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) - PA-20-185 | <a href="#">Link to Additional Information %</a> |
|   | Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required) - PA-20-184          | <a href="#">Link to Additional Information %</a> |
|   | NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) - PA-20-185 | <a href="#">Link to Additional Information %</a> |
|   | NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) - PA-20-185 | <a href="#">Link to Additional Information %</a> |

#### Funding Opportunity Title : Research Project Grant (Parent R01 Clinical Trial Required) - PA-20-183

Funding Agency : National Institutes of Health

**Description :**  
The NIH Research Project Grant supports a discrete, specified, circumscribed project in scientific areas that represent the investigators' specific interests and competencies and that fall within the mission of the participating NIH Institutes and Centers (ICs). All applications submitted to this Parent Funding Opportunity Announcement must **propose clinical trial(s)**.  
NIH defines a clinical trial as "A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes."  
Applicants should note that some NIH Institutes/Centers only accept applications proposing mechanistic studies that meet NIH's definition of a clinical trial through this funding opportunity announcement. A mechanistic study is designed to understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention. If the proposed research project includes clinical trial other than a mechanistic study that would be assigned to one of these ICs, applicants are advised to contact relevant **Scientific/Relevant staff** to discuss alternative mechanisms of support of these studies (<https://grants.nih.gov/grants/guide/contacts/Clinical-Trial-Parent-R01.htm>)

**Eligibility Information :** See the link below

**Award Budget :** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Award Period :** The scope of the proposed project should determine the project period. The maximum project period is 5 years.

**Open date :** 2020-05-05

**Deadline :** 08-05-2023 ; Multiple deadlines according with the NIH standard due dates cycles : Cycle I : February 5, Cycle II : June 5, Cycle III : October 5.

**Link to Additional Information :** <https://grants.nih.gov/grants/guide/pa-files/PA-20-183.html>

...specific interests and competencies of the 08-05-2023

...studies fall within the NIH definition of a clinical trial that prospectively assign human subjects to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes."  
...techniques, and points of view. These studies should be designed to understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention. If the proposed research project includes clinical trial other than a mechanistic study that would be assigned to one of these ICs, applicants are advised to contact relevant Scientific/Relevant staff to discuss alternative mechanisms of support of these studies (<https://grants.nih.gov/grants/guide/contacts/Clinical-Trial-Parent-R01.htm>)

Deadline

Topic

Agency

Description

Research Project Grant (Parent R01 Clinical Trial Required) - PA-20-183  
The NIH Research Project Grant supports a discrete, specified, circumscribed project in scientific areas that represent the investigators' specific interests and competencies and that fall within the mission of the participating NIH Institutes and Centers (ICs). All applications submitted to this Parent Funding Opportunity Announcement must **propose clinical trial(s)**.

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) - PA-20-185  
The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers based on their scientific missions.

This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).  
Visit the link down below for more information: [https://grants.nih.gov/grants/guide/contacts/Clinical-Trial-Parent-R01.htm](#)

NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) - PA-20-185  
The NIH Exploratory/Developmental Research Grant Program supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s).

Immunodeficiency Diseases  
Animal and plant health  
Biopharmaceuticals control methods  
Biotechnology-based products  
Birth defects and infant mortality  
Brain and Nervous system  
Cancer  
Cancer & bioinformatics  
Cancer Genetic  
Childhood obesity  
Chronic inflammation  
Clinical microbiology and infectious diseases  
Creative industries  
Ebola and filoviruses treatment and diagnosis  
Ethics and Research Integrity  
EU neighbourhood policies  
Exploratory/Developmental Research on biomedical, behavioral, and clinical science  
Gender equality  
Genetic

☐ Public ☒ Privé☒ Call ☐ Sourcing ☐TitleFunding agencyNCNCURLNC

### Description

B I U [bulleted list icon] [numbered list icon] [indent icon] [outdent icon] [align left icon] [align center icon] [align right icon] [justify icon] [font size dropdown] [font family dropdown] [font format dropdown] [bullet point icon] [numbered list icon] [link icon] [unlink icon] [insert icon] [undo icon] [redo icon]

NC

### Deadline

ii/mm/aaaa

### Deadlines

# Access Funding

Disease Area

### Multiple intervention areas

funding  
agency.

National Institutes of Health

Funding Opportunity Title

Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required) - PA-20-184

The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s).

This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate 'Clinical Trials Required' or 'Clinical Trial Optional' FOA.

### Description

The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers based on their scientific missions.

### Deadline

2023-05-08

Open date

2020-05-05

Award Type

Research and Development

Disease  
Area

### Multiple intervention areas

Access to the database

Email

Password

Login

Forgot your password? [Reset](#)

Don't have an account? [Register](#)

Project notice

Please enter your project data

Grants Office Templates and  
Guides

- [Personal cost](#)
- [Timesheet](#)



# Access Projects

ement

Laboratoire

Téléphone

Poste

Email

Projet

Bailleur de Fonds

Type de financement

Programme

Situation

jj/mm/aaaa

jj/mm/aaaa

Acronyme

Titre

Description

Lien du site

Mot clés

Remarque

Détails du budget +

Documentation +

Soumettre

Annuler

## Project management

Code

Situation

Bailleur de fond

Partenaire

Pays

Programme

Coordinateur

Laboratoires

Type de Financement

Date de début

Date de fin


chercher

Annuler

Résultat :


| Projet    | Type de Financement           | BF/Programme                                                  | PI/Labo                     | Titre                                                                                                                                                  | Partenaire                                                                                                                     | Budget       | Periode   | Action                                        |
|-----------|-------------------------------|---------------------------------------------------------------|-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------------|-----------|-----------------------------------------------|
| TBC/Actif | Subvention de financement R&D | Commission Européenne (CE)/ Seventh Framework Programme (FP7) | Mohamed fathi Diouani / TBC | Non-invasive volatiles test for canine leishmaniasis diagnosis <a href="#">voir plus</a>                                                               | Institut Pasteur de Tunis/Eesti Maailikool/Uppsala Universitet/N Vision Systems and Technologies SI/Universitatea Spiru Haret/ | 1 881 400,00 | 2021/2025 | <a href="#">Update</a> <a href="#">Delete</a> |
| TBC/Actif | Subvention de financement R&D | Université Federico II de Naples/ TBC                         | Lilia Zribi / TBC           | Agreement for co-operation between the university of naples Fedirico TT and IPT <a href="#">voir plus</a>                                              |                                                                                                                                |              | 2019/2024 | <a href="#">Update</a> <a href="#">Delete</a> |
| TBC/Actif | Subvention de financement R&D | Fondation Wellcome Trust/ TBC                                 | Balkiss Bouhaouala / TBC    | Developing the next generation of anti-venoms to improve management of cobra poisonings in low and middle incoming countries <a href="#">voir plus</a> |                                                                                                                                | 611 320,00   | 2021/2024 | <a href="#">Update</a> <a href="#">Delete</a> |

### Funding agencies




● Ministère de l'Enseignement Supérieur et de la Recherche Scientifique (MESRS) ● Institut Pasteur de Tunis ● Institut Pasteur Paris  
 ● Organisation Mondiale de la Santé (OMS) ● Commission européenne ● Others

### Programs



● Programme Collaboratifs Internes (PCI) ● Programme d'Encouragement des Jeunes Chercheurs (PEJC) ● Horizon 2020 (H2020)  
 ● Seventh Framework Programme (FP7) ● Programme d'Appui à la Qualité (PAQ)

### Projects Situations



### Project/Role



## TOP 10 2020

High-depth African genomes inform human migration and health [49.96]

Update on Immunodeficiency-Associated Vaccine-Derived Polioviruses - Worldwide, July 2018-December 2019 [17.59]

VapBC22 toxin-antitoxin system from Mycobacterium tuberculosis is required for pathogenesis and modulation of host immune response [14.14]

Toward personalization of asthma treatment according to trigger factors [10.79]

Genetic Approaches for Definitive Diagnosis of Agammaglobulinemia in Consanguineous Families [8.32]

Femtomolar direct voltammetric determination of circulating miRNAs in sera of cancer patients using an enzymeless biosensor [6.56]

Interleukin-17A polymorphisms predict the response and development of tolerance to FOLFOX chemotherapy in colorectal cancer treatment [5.99]

Determination of miRNAs in serum of cancer patients with a label- and enzyme-free voltammetric biosensor in a single 30-min step [5.83]

Metatranscriptomics of Tunisian phosphogypsum based on five bioinformatics pipelines: Insights for bioremediation

## 2177 Publications

### Result of research 134 Publications

1. Underlying Molecular Genetic Defects of Severe Combined Immunodeficiency in Tunisia  
Ben-Mustapha, I; Tezeghdenti, A; Al Baik, L; Al-Hissi, S; Lagueche, B; Sammoud, A; Ben-Jaballah, N; Mellouli, F; Bejaoui, M; Al-Mousa, H; Hawwari, A; Barbouche, MR;  
Published :OCT 2014 Source :JOURNAL OF CLINICAL IMMUNOLOGY IF :3.184 Volumes :34 Pages :S438 - S438

2. Consanguinity and rare disease in North Africa: Current situation and perspectives  
Romdhane, L; Abdelhak, S;  
Published :SEP 2014 Source :JOURNAL OF BIOTECHNOLOGY IF :2.871 Volumes :185 Pages :S12 - S13

3. Prevalence and determinants of Leishmania major infection in emerging and old foci in Tunisia  
Bettaieb, J; Toumi, A; Chlif, S; Chelghaf, B; Boukthir, A; Gharbi, A; Ben Salah, A;  
Published :AUG 20 2014 Source :PARASITES & VECTORS IF :3.43 Volumes :7




4. Molecular Tools for Understanding Eco-Epidemiology, Diversity and Pathogenesis of Leishmania Parasites  
Guerbouj, S; Mkada-Driss, I; Guizani, I;  
Published :2014 Source :LEISHMANIASIS - TRENDS IN EPIDEMIOLOGY, DIAGNOSIS AND TREATMENT Pages :61 - 103

5. An investigation on vertical transmission of Leishmania infantum in experimentally infected dogs and assessment of offspring's infectiousness potential by xenodiagnosis  
Slimane, TB; Chouh, E; Ahmed, SBH; Chelbi, I; Barhoumi, W; Cherni, S; Zoghalmi, Z; Gharbi, M; Zhioua, E;  
Published :DEC 15 2014 Source :VETERINARY PARASITOLOGY Volumes :206 Pages :282 - 286




6. Mycobacterial Infections in Tunisian Primary Immunodeficiency Patients  
Mekki, N; Ben-Mustapha, I; Ben-Ali, M; Boughammoura, L; Guediche, N; Sfar, MT; Sammoud, A; Hchicha, M; Mahfoudh, A; Chemli, J; Bejaoui, M; Barbouche, MR;  
Published :OCT 2014 Source :JOURNAL OF CLINICAL IMMUNOLOGY IF :3.184 Volumes :34 Pages :S255 - S256

**HAL**  
archives-ouvertes.fr

OPEN  ACCESS

Gestion de

Admin View

Admin View

Visitor view

Ajout par

Ajouter par fichier

Trouver les doublons

Normalisation

PUBMED

HAL

Nombre de publications: 2177

|    | TITRE                                                                                                                                                                                                                                                      | Résumé                                                                                                  | PubMed ID         | Source |                                                                                                                                                                                                                                                             |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|-------------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. | <b>Effect of process parameters on quality attributes of Lben: Correlation between physicochemical and sensory properties</b><br><br><u>DOI : 10.1016/j.lwt.2021.112987</u><br><u>Publication year : 2022</u><br><u>Date d'ajout : 2022-04-19 00:40:50</u> | The aim of this work is to investigate for the first time, the interaction effect between process pa... | NC                | WOS    |    |
| 2. | <b>Prognostic value of matrix metalloproteinase 2 protein expression in ovarian cancer is age- and stage-dependent</b><br><br><u>DOI : 10.31083/j.ejgo4301010</u><br><u>Publication year : 2022</u><br><u>Date d'ajout : 2022-04-19 12:18:23</u>           | Objective: Matrix metalloproteinase 2 (MMP2) has been associated with tumor development and invasion... |                   | WOS    |    |
| 3. | <b>The simplex simulation as a tool to reveal publication strategies and citation factors</b><br><br><u>DOI : 10.1007/s11192-021-04198-1 EA NOV 2021</u><br><u>Publication year : 2022</u><br><u>Date d'ajout : 2022-04-19 09:05:34</u>                    | Scientists' evaluations are commonly made by h-index calculated from citation levels of published pa... | NC                | WOS    |    |
| 4. | <b>Identification and characterization of multidrug-resistant ESBL-</b>                                                                                                                                                                                    | Aims: Molecular characterization of                                                                     | 34252258 DA 2022- | WOS    |    |

Access  
Metrics

Année Source JCR IPT Auteur Type de document Facteur d'impact IF Med &amp; Moy Pays Leadership


| Année | Publications |
|-------|--------------|
| 1973  | 1            |
| 1976  | 1            |
| 1977  | 4            |
| 1978  | 2            |
| 1979  | 2            |
| 1980  | 1            |
| 1981  | 1            |
| 1982  | 1            |
| 1984  | 2            |
| 1985  | 2            |
| 1986  | 2            |



moyenne IF médiane(50%) 1er quartile(25%) 3eme quartile(75%) Interquartile

Année Source JCR IPT Auteur Type de document Facteur d'impact IF Med &amp; Moy Pays Leadership

| Pays        | Publications |
|-------------|--------------|
| France      | 561          |
| USA         | 206          |
| Spain       | 86           |
| England     | 94           |
| Italy       | 76           |
| Belgium     | 55           |
| Morocco     | 81           |
| Algeria     | 56           |
| Germany     | 65           |
| Switzerland | 50           |
| Netherlands | 32           |
| Iran        | 56           |



Publications Metrics Projects Funding Gestion utilisateurs Najet Hadhri ▾

|      |                 |       |       |       |       |     |                 |       |       |        |       |     |
|------|-----------------|-------|-------|-------|-------|-----|-----------------|-------|-------|--------|-------|-----|
| 1997 | 1.4512652738102 | 1.15  | 0.401 | 1.948 | 0.400 | 26  | 1.410777494043  | 1.15  | 0.401 | 1.949  | 1.400 | 27  |
| 1998 | 1.509588202081  | 1.366 | 0.548 | 2.068 | 1.52  | 17  | 1.447473709205  | 1.366 | 0.526 | 2.068  | 1.542 | 19  |
| 1999 | 1.6548714265686 | 1.240 | 0.803 | 2.831 | 1.948 | 14  | 1.4562271049676 | 1.911 | 0.968 | 10.426 | 9.406 | 22  |
| 2000 | 1.918666748934  | 1.175 | 1.439 | 2.852 | 1.413 | 15  | 4.4759999733954 | 2.852 | 1.485 | 9.249  | 7.754 | 23  |
| 2001 | 2.1348231957750 | 1.325 | 0.43  | 1.693 | 1.263 | 26  | 3.2676176739996 | 1.434 | 0.657 | 3.586  | 2.929 | 34  |
| 2002 | 1.7953333324856 | 0.963 | 0.449 | 2.202 | 1.753 | 18  | 3.5207500259062 | 1.686 | 0.57  | 6.696  | 6.126 | 24  |
| 2003 | 2.1698047457604 | 1.626 | 1.345 | 2.971 | 1.626 | 21  | 3.679405242806  | 2.034 | 1.509 | 3.489  | 1.96  | 25  |
| 2004 | 2.688285701198  | 1.862 | 0.902 | 4.033 | 3.131 | 28  | 2.8826363664885 | 2.331 | 0.972 | 4.033  | 3.061 | 33  |
| 2006 | 2.4029189130744 | 2.056 | 1.212 | 3.537 | 2.325 | 37  | 2.4323659393554 | 2.255 | 0.978 | 3.537  | 2.559 | 46  |
| 2006 | 2.921832789193  | 2.442 | 1.007 | 3.159 | 2.152 | 33  | 3.1775476020716 | 2.509 | 1.007 | 3.445  | 2.430 | 42  |
| 2007 | 1.973272736761  | 1.833 | 1.167 | 2.662 | 1.495 | 44  | 2.409836156605  | 1.862 | 1.437 | 2.844  | 1.407 | 61  |
| 2008 | 2.967044460864  | 2.195 | 1.561 | 3.139 | 1.578 | 45  | 3.0958695929983 | 2.364 | 1.652 | 3.555  | 1.903 | 69  |
| 2009 | 2.5488998979486 | 2.373 | 1.705 | 3.287 | 1.582 | 70  | 2.7589479177346 | 2.553 | 1.921 | 3.479  | 1.558 | 96  |
| 2010 | 2.43736563383   | 2.446 | 1.265 | 2.56  | 1.695 | 61  | 2.833191069551  | 2.546 | 1.512 | 3.328  | 1.816 | 79  |
| 2011 | 2.364464782913  | 2.588 | 1.462 | 3.077 | 1.615 | 71  | 2.475168898488  | 2.57  | 1.762 | 2.961  | 1.199 | 90  |
| 2012 | 2.636124803016  | 2.634 | 1.348 | 3.492 | 2.144 | 72  | 2.8368704349545 | 2.787 | 1.672 | 3.689  | 2.017 | 88  |
| 2013 | 2.906488139993  | 2.27  | 1.319 | 2.654 | 1.335 | 76  | 3.119168810873  | 2.33  | 1.449 | 3.251  | 1.802 | 91  |
| 2014 | 2.93828931886   | 2.211 | 1.364 | 3.234 | 1.87  | 96  | 3.078451643273  | 2.482 | 1.517 | 3.234  | 1.717 | 124 |
| 2015 | 3.3482222157718 | 2.647 | 1.791 | 3.948 | 2.157 | 90  | 3.2883898527935 | 2.69  | 1.76  | 3.948  | 2.188 | 106 |
| 2016 | 1.6267070388888 | 2.081 | 1.63  | 3.138 | 1.608 | 101 | 2.9607161609247 | 2.453 | 1.636 | 3.106  | 1.672 | 146 |

en pour tout type des DOs

# Web-based Research Information Management




**Institutional level**



**Department level**



**Individual level**



# Forthcoming Development



Public Engagement   Science Education

Open Science

- Inclusive approach
- Impact monitoring
- Increase dissemination



# INSIGHT ACCESS TEAM



EYA KARROUCH



ASMA FERCHICHI



RAGHDA BSIBES



ZEINEB AFIFI



HOUSSEM MAGHRAOUI



NAJET HADHRI



KHOULOUDE YOUSSEFI

**PHIND access** **Webinar**

**Information management for research output valorization & performance monitoring**

**April 21, 2022**  
**10:00 Tunis time**  
 For access details visit: [www.phindaccess.org](http://www.phindaccess.org)

Project funded by the European Commission under the Horizon program Training PHIndAccess is a project coordinated by the Institut Pasteur de Tunis


ONST


PHIND access

www.phindaccess.org



|                |     |
|----------------|-----|
| Tunisia        | 103 |
| Morocco        | 5   |
| Iraq           | 4   |
| Nigeria        | 2   |
| France         | 2   |
| MALAYSIA       | 1   |
| Spain          | 1   |
| United Kingdom | 1   |






## The Directory of Research Information System (DRIS)



[www.iaccess.pasteur.tn](http://www.iaccess.pasteur.tn)



Najet Hadhri  
Head of Grants Office  
Institut Pasteur de Tunis  
@ nhadhri@pasteur.utm.tn

# THANKS!

